Multiple Myeloma

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

Featured

FDA Approval
fda banner on laptop
FDA Approval
FDA Grants Accelerated Approval to Zenbexus for Previously Treated Multiple Myeloma
08/19/2026
Anthony Calabro, MA
The FDA granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with multiple myeloma previously treated with a proteasome...
08/19/2026
Conference Coverage
Drs Mikhael and Watson
Conference Coverage
Video Recap—Multiple Myeloma Across the Care Continuum
08/13/2026
Brittany Watson, MD, MPH; Joseph Mikhael, MD, MEd, FRCPC
In this video, Brittany Watson, MD, MPH, FAAFP, DABOM and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of primary care in the early recognition and diagnosis of multiple myeloma, including the...
08/13/2026
Timelines
Notable FDA Approvals
Timelines
Notable FDA Approvals in July
07/27/2026
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
07/27/2026

Interactive Features

Pop Quiz
physician at desk
Pop Quiz
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
12/17/2025
Ashton L. Stahl
As researchers continue exploring early-intervention strategies for high-risk smoldering multiple myeloma, understanding the basic pathophysiology of plasma cell disorders (and the targets of emerging...
12/17/2025

Clinical Insights

Multidisciplinary Dialogue, Ep. 8
harrison
Multidisciplinary Dialogue, Ep. 8
Renal Tubular Acidosis, Metabolic Alkalosis
09/02/2024
In this episode, Anil Harrison, MD, speaks with Dharminder Singh, MD, about the evaluation of renal tubular acidosis (RTA) and how to evaluate metabolic alkalosis. The first patient case presentation is a...
09/02/2024
expert Q&A
richter headshot
expert Q&A
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual...
10/18/2022